Publicaties

Onderstaand vindt u een overzicht van de publicaties en proefschriften waarbij gebruik is gemaakt van GIANTT data. Sommige artikelen zijn vrij opvraagbaar online, maar voor sommige is een abonnement vereist. Desgewenst kunnen we u een privé kopie van de publicatie opsturen. Zie daarvoor de contact pagina.

Internationaal

2024

de Vries ST, de Vos S, Oktora MP, Denig P. Sex disparities in medication changes after metformin initiation are associated with small, clinically non-relevant, sex differences in HbA1c levels during follow-up. Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5802.

2023

Oktora MP, de Vos S, de Vries ST, Hak E, Denig P. Sex disparities in treatment patterns after metformin initiation among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf. 2023 Dec;32(12):1395-1405. doi: 10.1002/pds.5672. Epub 2023 Jul 31.

de Vries ST, Ambrož M, Denig P. Man-vrouwverschillen in voorgeschreven medicatie bij DM2. Huisarts Wetenschap 2023; 9, 66, 20–23.

Ambrož M, Geelink M, Smits KPJ, de Vries ST, Denig P. Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care. Diabet Med. 2023;40(1):e14987. doi: 10.1111/dme.14987. 

Zhang F, de Bock GH, Denig P, Landman GW, Zhang Q, Sidorenkov G. Role of Serum Lipids, Blood Glucose and Blood Pressure in Breast Cancer Risk for Women with Type 2 Diabetes Mellitus. Clin Epidemiol. 2023;15:109-121. doi: 10.2147/CLEP.S386471. 

2022

Ambrož M, de Vries ST, Hoogenberg K, Denig P. Less Timely Initiation of Glucose-Lowering Medication Among Younger and Male Patients With Diabetes and Similar Initiation of Blood Pressure-Lowering Medication Across Age and Sex: Trends Between 2015 and 2020. Front Pharmacol. 2022 May 12;13:883103. doi: 10.3389/fphar.2022.883103. eCollection 2022.

2021

Ambrož M, de Vries ST, Hoogenberg K, Denig P. Trends in HbA1c thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients. Pharmacoepidemiol Drug Saf. 2021; 30(1):37-44. 

Ambrož M, de Vries ST, Hoogenberg K, Denig P. Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives. Front. Pharmacol. 2021, 12:728911.

de Haan-Du J, Landman GWD, Kleefstra N, Schrijnders D, Manders M, Bos ACRK, Tromp-van Driel C, Denig P, Groenier KH, de Bock GH. Glycemic Control for Colorectal Cancer Survivors Compared to Those without Cancer in the Dutch Primary Care for Type 2 Diabetes: A Prospective Cohort Study. Cancers (Basel). 2021; 13(11):2767.

Oktora MP, Alfian SD, Bos HJ, Schuiling-Veninga CCM, Taxis K, Hak E, Denig P. Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle-aged people treated for diabetes. Br J Clin Pharmacol. 2021; 87(7):2807-2817.

Ambrož M, de Vries ST, Vart P, Dullaart RPF, Roeters van Lennep J, Denig P, Hoogenberg K. Sex Differences in Lipid Profile across the Life Span in Patients with Type 2 Diabetes: A Primary Care-Based Study.  J Clin Med. 2021; 10(8):1775. doi: 10.3390/jcm10081775.

2020

Crutzen S, Nagaraj SB, Taxis K, Denig P. Identifying patients at increased risk of hypoglycaemia in primary care: Development of a machine learning-based screening tool. Diabetes Metab Res Rev. 2020:e3426. 

Ambrož M, de Vries ST, Sidorenkov G, Hoogenberg K, Denig P. Changes in blood pressure thresholds for initiating antihypertensive medication in patients with diabetes: a repeated cross-sectional study focusing on the impact of age and frailty. BMJ Open. 2020; 10(9):e037694. 

Vos RC, den Ouden H, Daamen LA, Bilo HJG, Denig P, Rutten GEHM.Population-based screen-detected type 2 diabetes mellitus is associated with less need for insulin therapy after 10 years. BMJ Open Diabetes Res Care. 2020; 8(1):e000949. 

2019

Schmidt AF, Heerspink HJL, Denig P, Finan C, Groenwold RHH. When drug treatments bias genetic studies: Mediation and interaction. PLoS One. 2019;14(8):e0221209. 

Nagaraj SB, Sidorenkov G, van Boven JFM, Denig P. Predicting short- and long-term glycated haemoglobin response after insulin initiation in patients with type 2 diabetes mellitus using machine-learning algorithms. Diabetes Obes Metab 2019; 21(12):2704-2711

Martono DP, Heerspink HJL, Hak E, Denig P, Wilffert B. No significant association of type 2 diabetes-related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives. Diabetes Obes Metab 2019; 21(10):2267-2273

2018

Sidorenkov G, van Boven JF, Hoekstra T, Nijpels G, Hoogenberg K, Denig P. HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups. Diabetes Obes Metab 2018; 20(8):1957-1964

Apperloo EM, Pena MJ, de Zeeuw D, Denig P, Heerspink HJ. Individual variability in response to renin-angiotensin-aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: a primary care cohort study. Diabetes Obes Metab 2018; 20(6):1377-1383

Wildeboer A, du Pon E, Schuling J, Haaijer-Ruskamp FM, Denig P. Views of general practice staff about the use of a patient-oriented treatment decision aid in shared decision making for patients with type 2 diabetes: a mixed-methods study. Health Expect 2018; 21(1):64-74

2017 

Smits KP, Sidorenkov G, Kleefstra N, Bouma M, Meulepas M, Voorham J, Navis G, Bilo HJ, Denig P. Development and validation of prescribing quality indicators for patients with type 2 diabetes. Int J Clin Pract. 2017; 71(1).

Smits KP, Sidorenkov G, Navis G, Bouma M, Meulepas M, Bilo HJ, Denig P. Prescribing Quality and Prediction of Clinical Outcomes in Patients With Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care 2017; 40(7):e83-84

2016

Pouwels KB, Voorham J, Hak E, Denig P. Identification of major cardiovascular events in patients with diabetes using primary care data. BMC Health Serv Res. 2016; 16(1):110

Cho YY, Sidorenkov G, Denig P. Role of Patient and Practice Characteristics in Variance of Treatment Quality in Type 2 Diabetes between General Practices. PLoS One 2016; 11(11):e0166012

Huang Y, Haaijer-Ruskamp FM, Voorham J.Comparing the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal function decline in diabetes. J Comp Eff Res. 2016; 5(3):229-37

Huang Y, Voorham J, Haaijer-Ruskamp FM.Using primary care electronic health record data for comparative effectiveness research: experience of data quality assessment and preprocessing in The Netherlands. J Comp Eff Res. 2016; 5(4):345-54

Martono DP, Hak E, Lambers Heerspink H, Wilffert B, Denig P.Predictors of HbA1c levels in patients initiating metformin. Curr Med Res Opin 2016; 32(12):2021-2028

de Vries FM, Voorham J, Hak E, Denig P. Prescribing patterns, adherence and LDL- cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study. Int J Clin Pract 2016;70(6):482-92

Smits KP, Sidorenkov G, Bilo HJ, Bouma M, van Ittersum FJ, Voorham J, Navis GJ, Denig P. Development and initial validation of prescribing quality indicators for patients with chronic kidney disease. Nephrol Dial Transplant.2016; 31(11):1876-1886

2015

de Vries FM, Voorham J, Hak E, Denig P. Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients. Curr Med Res Opin. 2015; 31(12):2197-206.

2014

de Vries ST, Voorham J, Haaijer-Ruskamp FM, Denig P. Potential overtreatment and undertreatment of diabetes in different patient age groups in primary care after the introduction of performance measures. Diabetes Care. 2014; 37(5):1312-20

Denig P, Schuling J, Haaijer-Ruskamp FM, Voorham J.Effects of a patient-oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial. BMJ 2014; 349:g5651.

de Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, Denig P.Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014; 76(2):134-8.

2013

Sidorenkov G, Voorham J, de Zeeuw D, Haaijer-Ruskamp FM, Denig P.Do treatment quality indicators predict cardiovascular outcomes in patients with diabetes? PLoS One 2013; 8(10):e78821.

Sidorenkov G, Voorham J, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database. BMJ Qual Saf 2013;22(4):339-47.

Elissen AM, Adams JL, Spreeuwenberg M, Duimel-Peeters IG, Spreeuwenberg C, Linden A, Vrijhoef HJ.Advancing current approaches to disease management evaluation: capitalizing on heterogeneity to understand what works and for whom. BMC Med Res Methodol 2013; 14;13(1):40.

Hellemons ME, Denig P, de Zeeuw D, Voorham J, Lambers Heerspink HJ.Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort. Nephrol Dial Transplant. 2013; 28(3):706-15.

Sidorenkov G, Voorham J, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. Association between performance measures and glycemic control among patients with diabetes in a community-wide primary care cohort. Med Care. 2013; 51(2):172-9.

2012

Denig P, Dun M, Schuling J, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J. Design and effect of a patient-oriented treatment decision aid for risk factor management in patients with diabetes (PORTDA-diab): protocol for a pragmatic, randomised trial. Trials 2012; 13(1):219.

de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetes patients: a meta-analysis. Drugs 2012; 72(18):2365-73

Martirosyan L, Haaijer-Ruskamp FM, Braspenning J, Denig P.Development of a minimal set of prescribing quality indicators for diabetes management on a general practice level. Pharmacoepidemiol Drug Saf. 2012; 21(10): 1053-9.

Voorham J, Haaijer-Ruskamp FM, Stolk RP, Wolffenbuttel BHR, Denig P.Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus – a cohort study. PLoS One 2012;7(6):e38707.

Martirosyan L, Markhorst J, Denig P, Haaijer-Ruskamp FM, Braspenning J. A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators. BMC Health Services Research 2012; 12: e191.

Elissen AMJ, Duimel-Peeters IGP, Spreeuwenberg C, Spreeuwenberg M, Vrijhoef HJM. Toward tailored disease management for type 2 diabetes. Am J Manag Care 2012; 18(10):619-630.

Härmark L, Alberts S, van Puijenbroek E, Denig P, van Grootheest K. Representativeness of diabetes patients participating in a web-based adverse drug reaction monitoring system. Pharmacoepi & Drug Safety 2012; 22(3):250-255

Voorham J, Haaijer-Ruskamp FM, Stolk RP, Wolffenbuttel BHR, Denig P. Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus – a cohort study. PLoS One 2012; 7(6):e38707.

2011

Sidorenkov G, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness. PLoS One. 2011; 6(9):e24278.

Sidorenkov G, Haaijer-Ruskamp FM, de Zeeuw D, Bilo H, Denig P. Review: relation between quality-of-care indicators for diabetes and patient outcomes: a systematic literature review. Med Care Res Rev. 2011; 68(3):263-89.

Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BH, Stolk RP, Denig P; Groningen Initiative to Analyze Type 2 Diabetes Treatment Group.Medication adherence affects treatment modifications in patients with type 2 diabetes. Clin Ther. 2011; 33(1):121-34.

2010

Voorham J, Haaijer-Ruskamp FM, van der Meer K, de Zeeuw D, Wolffenbuttel BH, Hoogenberg K, Denig P; GIANTT-Group. Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study. Pharmacoepidemiol Drug Saf. 2010; 19(10):1078-86.

Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BH, Stolk RP, Denig P; Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) Group.Cardiometabolic treatment decisions in patients with type 2 diabetes: the role of repeated measurements and medication burden. Qual Saf Health Care. 2010; 19(5):411-5.

Martirosyan L, Arah OA, Haaijer-Ruskamp FM, Braspenning J, Denig P. Methods to identify the target population: implications for prescribing quality indicators. BMC Health Serv Res. 2010; 26;10:137.

Martirosyan L, Voorham J, Haaijer-Ruskamp FM, Wolffenbuttel BHR, Denig P.A systematic literature review: Prescribing quality indicators for type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiology Drug Safety 2010; 19(4):319-34.

2009

AB E, Denig P, van Vliet T, Dekker JH. Reasons of general practitioners for not prescribing lipid-lowering medication to diabetes mellitus type II patients: a qualitative study. BMC Fam Practice 2009; 10:24.

Vink NM, Klungel OH, Stolk RP, Denig P. Comparison of various measures for assessing medication refill adherence using prescription data. Pharmacoepidemiol Drug Saf. 2009; 18(2):159-65.

2008

Voorham J, Denig P, Wolffenbuttel BHR, Haaijer-Ruskamp FM. Cross-sectional versus sequential quality indicators of risk factor management in patients with type 2 diabetes. Med Care 2008; 46(2):133-41.

Voorham J, Haaijer-Ruskamp FM, Stolk RP, Wolffenbuttel BHR, Denig P; Groningen Initiative to Analyze Type 2 Diabetes Treatment Group. The influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes. Diabetes Care 2008; 31(3):501-3.

Martirosyan L, Braspenning J, Denig P, de Grauw WJC, Bouma M, Storms F, Haaijer-Ruskamp FM. Prescribing quality indicators of type 2 diabetes mellitus ambulatory care. Qual Safety Health care 2008; 17:318-23

2007

Voorham J, Denig P, on behalf of GIANTT. Computerized extraction of information on the quality of diabetes care from free text in electronic patient records of general practitioners. J Am Med Inform Assoc. 2007;14(3):349-54.

Nationaal

Denig P, de Vries ST. Medicatie DM2 – Man-vrouwverschillen. TvPO 2024; 23 maart: 22-23.

Schuling J, Voorham J, Haaijer FM, Denig P. Effects of a patient oriented decision aid for prioritising treatment goals in diabetes:pragmatic randomised controlled trial]. Ned Tijdschr Geneeskd 2015;159:A8691. Dutch.

Voorham J, Haaijer-Ruskamp FM, van der Meer K, de Zeeuw D, Wolffenbuttel BHR,Hoogenberg K, Denig P. Kwaliteit van de behandeling van type 2-diabetes: resultaten van het GIANTT-project 2004-2007. Nederlands Tijdschrift voor Geneeskunde 2010 154 (4): 159-166.

Haaijer-Ruskamp FM, Voorham J, Denig P, GIANTT groep Groningen. Evaluatie van kwaliteit van diabeteszorg op basis van het HIS. Patient Care 2007, 34 (3): 56-60.

Voorham J, Denig P, GIANTT groep. Evaluatie van de kwaliteit van zorg voor type 2 diabetes op basis van automatische gegevensextractie uit deels ongestructureerde EPDs (congresboek 16e EZD symposium, Ede, 26 sept 2006)

Denig P, c.s. Reusachtige inzichten: GIANTT-project brengt kwaliteit diabeteszorg in beeld. Medisch Contact 2006; 61:1799-1802.

Proefschriften